argenx to Participate in Upcoming Virtual Investor Conferences
November 9, 2020 Breda,
the Netherlands / Ghent, Belgium – argenx (Euronext &
Nasdaq: ARGX), a global immunology company committed to improving
the lives of people suffering from severe autoimmune diseases and
cancer, today announced that management will participate in several
upcoming investor conferences:
- Guggenheim Healthcare Talks | Idea Forum | 2nd Annual
Neuro/Immunology Day on November 16, 2020. Management will
participate in 1x1 meetings.
- Stifel 2020 Virtual Healthcare Conference. Fireside chat on
November 17, 2020 at 2:00 p.m. ET.
- Wolfe Research Virtual Healthcare Conference on November 19,
2020. Management will participate in 1x1 meetings.
- Piper Sandler 32nd Annual Virtual Healthcare Conference on
December 1, 2020. Fireside chat available to conference
- 3rd Annual Evercore ISI HealthCONx Conference Virtual. Fireside
chat on December 2, 2020 at 9:40 a.m. ET.
About argenxargenx is a global
immunology company committed to improving the lives of people
suffering from severe autoimmune diseases and cancer. Partnering
with leading academic researchers through its Immunology Innovation
Program (IIP), argenx aims to translate immunology breakthroughs
into a world-class portfolio of novel antibody-based medicines.
argenx is evaluating efgartigimod in multiple serious autoimmune
diseases, and cusatuzumab in hematological cancers in collaboration
with Janssen. argenx is also advancing several earlier stage
experimental medicines within its therapeutic franchises. argenx
has offices in Belgium, the United States, and Japan. For more
information, visit www.argenx.com and follow us on LinkedIn at
For further information, please contact:
Beth DelGiacco, Vice President, Corporate Communications &
Investor Relations +1 518 424 firstname.lastname@example.org
Joke Comijn, Director Corporate Communications & Investor
Relations (EU)+32 (0)477 77 29 44+32 (0)9 310 34